Why the study?
Does P2Y12 inhibitor monotherapy with ticagrelor reduce mortality and bleeding risk compared to standard DAPT in patients undergoing percutaneous coronary intervention?
Does P2Y12 inhibitor monotherapy with ticagrelor reduce mortality and bleeding risk compared to standard DAPT in patients undergoing percutaneous coronary intervention?
In patients undergoing PCI, P2Y12 monotherapy with ticagrelor may reduce mortality and bleeding risk compared to standard DAPT without increasing ischemic events.
Answers are grounded in this paper and cite their sources.
Ticagrelor monotherapy may reduce post-PCI mortality and bleeding; leaves open need for larger confirmatory trials.
In comparison to standard DAPT, P2Y12 inhibitor monotherapy with ticagrelor may lead to a reduced mortality. The clinical benefits are driven by a reduction of bleeding risk without ischemic risk trade-off.
No takes yet. Share an insight, caveat, or question.
Casula et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: